RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $68
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza maintains an Outperform rating on Pacira BioSciences (NASDAQ:PCRX), but lowers the price target from $70 to $68.

August 04, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Pacira BioSciences, but lowers the price target from $70 to $68.
The news is directly related to Pacira BioSciences. While the Outperform rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook for the company's stock in the short term. However, the impact on the stock price is uncertain as the rating remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100